8-K: Replimune Announces Positive Topline Data for RP1 in Anti-PD1 Failed Melanoma, BLA Submission Planned

Replimune's RP1 combined with nivolumab shows a 33.6% overall response rate in anti-PD1 failed melanoma patients, with all responses lasting over six months.

Summary

• Replimune Group, Inc. announced positive topline results from the primary analysis of the IGNYTE clinical trial for RP1 combined with nivolumab in patients with anti-PD1 failed melanoma.
• The independent central review showed an overall response rate of 33.6% by modified RECIST 1.1 criteria and 32.9% by RECIST 1.1 criteria.
• All responses were durable, lasting more than 6 months, with a median duration of response exceeding 35 months.
• The study included 140 patients who had progressed on prior anti-PD1 therapy.
• RP1 combined with nivolumab was generally well-tolerated, with mainly Grade 1-2 constitutional-type side effects observed.
• The company plans to submit the full primary analysis data for presentation at an upcoming medical congress and intends to submit a Biologics License Application (BLA) in the second half of 2024.
• The first patient is expected to be enrolled in the IGNYTE-3 confirmatory trial in Q3 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a high response rate and durable responses, along with a favorable safety profile. The company is also progressing towards BLA submission and commercialization, which are all positive indicators for investors.

Positives

• The overall response rate of 33.6% by modified RECIST 1.1 criteria is a significant improvement over the 6-7% response rate typically seen with further single-agent anti-PD1 therapy in this setting.
• The median duration of response exceeding 35 months is highly encouraging, indicating a durable benefit for patients.
• The safety profile of RP1 combined with nivolumab is favorable, with mainly Grade 1-2 side effects.
• The company is on track to submit a BLA in the second half of 2024, indicating progress towards commercialization.
• The IGNYTE-3 confirmatory trial is expected to begin in Q3 2024, further supporting the potential of RP1.

Negatives

• There were some Grade 4 adverse events, including one each of lipase increased, alanine aminotransferase increased, blood bilirubin increased, cytokine release syndrome, myocarditis, hepatic cytosis and splenic rupture, although no Grade 5 events were reported.
• The treatment-related adverse events included fatigue, chills, pyrexia, nausea, and other constitutional-type events, which may impact patient comfort.

Risks

• The company's ability to obtain regulatory approval for RP1 is subject to the FDA's review of the BLA submission.
• The success of the IGNYTE-3 confirmatory trial is crucial for the commercialization of RP1.
• The company faces competition from other therapies in the melanoma treatment landscape.
• There are risks associated with the manufacturing and commercialization of RP1, including scaling up production and managing costs.
• The company's future performance is subject to various risks and uncertainties, including those related to clinical trial results, regulatory approvals, and market conditions.

Future Outlook

The company plans to submit a BLA for RP1 in the second half of 2024 and is preparing for a commercial launch next year. They also plan to present the full primary analysis data at an upcoming medical congress and are initiating the IGNYTE-3 confirmatory trial in Q3 2024.

Management Comments

• Sushil Patel, Ph.D., CEO of Replimune, stated that the strength of the IGNYTE data and safety profile highlights the potential of RP1 in a difficult treatment setting.
• The CEO also expressed confidence in the path forward based on the compelling results and recent FDA interactions.

Industry Context

This announcement is significant in the context of the melanoma treatment landscape, where there is a high unmet need for patients who have progressed on anti-PD1 therapy. The results suggest that RP1 combined with nivolumab could be a valuable option for these patients, potentially filling a gap in current treatment options.

Comparison to Industry Standards

• The 33.6% overall response rate (ORR) observed in the IGNYTE trial is significantly higher than the 6-7% response rate typically seen with further single-agent anti-PD1 therapy in patients who have progressed on prior anti-PD1 treatment, as cited in the document referencing Mooradian MJ, et al. Oncology. 2019 and Beaver JA, et al. Lancet Oncol. 2018.
• The median duration of response exceeding 35 months is also notable, as many other treatments in this setting have shorter durations of response. For example, BRAF-targeted therapy responses are generally transient, as noted in the document referencing Dixon-Douglas JR, et al. Curr Oncol Rep. 2022.
• While TIL therapy can achieve response rates of around 30%, it is associated with high toxicity, with nearly all patients experiencing grade 4 toxicity, as noted in the document referencing US Food and Drug Administration. BLA clinical review and evaluation AMTAGVI. BLA 125773. The safety profile of RP1 combined with nivolumab appears more favorable in comparison.
• The combination of nivolumab and ipilimumab is another potential option, but it is associated with high toxicity, as noted in the document referencing Pires da Silva I, et al. Lancet Oncol. 2021 and VanderWalde AM, et al. Presented at the American Association of Cancer Research Annual Meeting 2022. The RP1 combination appears to have a better safety profile.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and progress towards BLA submission.
• Patients with anti-PD1 failed melanoma may benefit from a new treatment option with a favorable risk-benefit profile.
• Employees of Replimune may be motivated by the positive results and progress towards commercialization.
• The company's suppliers and partners may see increased business opportunities as the company moves closer to commercialization.

Next Steps

• The company plans to submit the full primary analysis data for presentation at an upcoming medical congress.
• The company intends to submit a Biologics License Application (BLA) in the second half of 2024.
• The first patient is expected to be enrolled in the IGNYTE-3 confirmatory trial in Q3 2024.

Key Dates

Keywords

RP1, nivolumab, melanoma, anti-PD1, oncolytic immunotherapy, clinical trial, IGNYTE, BLA, response rate, duration of response